Poster-Quality of Life and Outcomes
October 25, 2021
Patient-Reported Outcome Measures in Multiple Sclerosis Clinical Trials: Critical Assessment and Insights from People Living with Multiple Sclerosis
Background: Multiple sclerosis (MS) clinical trials often include patient-reported outcomes (PROs) to quantify treatment effects not...
Poster-Disease-modifying Therapy
October 25, 2021
Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study
Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years
Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...